New cancer drug TJ101 enters first human trials for advanced tumors
NCT ID NCT07181473
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 1 trial is testing TJ101, an experimental antibody-drug conjugate that delivers chemotherapy directly to cancer cells. It is for adults with advanced or metastatic solid tumors (lung, prostate, esophageal, and others) who have run out of standard options. The study aims to find the safest dose and see if the drug can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TJ101 (an antibody-drug conjugate that targets EGFR and B7H3, delivering a chemotherapy drug directly to cancer cells)
What this could lead to
If this trial succeeds, it could point toward a new treatment option for advanced solid tumors like lung, prostate, and esophageal cancers that have not responded to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 200 participants, so the drug may not prove effective or may have significant side effects. The results may not apply to all patients or tumor types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Florida Cancer Specialists & Research Institute
RECRUITINGOrlando, Florida, 32827, United States
Contact Phone: •••-•••-••••
-
Henan Cancer Hospital
NOT_YET_RECRUITINGZhengzhou, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Oncology Consultants
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sarah Cannon Research Institute (SCRI)
RECRUITINGNashville, Tennessee, 37203, United States
Contact Phone: •••-•••-••••
-
Shanghai East Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Sir Run Run Shaw Hospital
NOT_YET_RECRUITINGHangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Union Hospital of Tongji Medical College
NOT_YET_RECRUITINGWuhan, Hubei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact